TN2014000532A1 - N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products - Google Patents

N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products

Info

Publication number: TN2014000532A1
Authority: TN; Tunisia
Prior art keywords: arylcarboxamides; quinolin; yloxy; hetero; cyclohexyl
Prior art date: 2012-06-26

Application number

TN2014000532A

Other languages

English (en)

Inventor

Duy Nguyen

Gimenez Hortensia Faus

Benjamin Bader

Silke Köhr

Martin Fritsch

Hermann List Of Legal Sole Klara Muno Helga Künzer

Original Assignee

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-26

Filing date

2014-12-25

Publication date

2016-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48699019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000532(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-25 Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG

2016-03-30 Publication of TN2014000532A1 publication Critical patent/TN2014000532A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Quinoline Compounds (AREA)
Apparatus For Radiation Diagnosis (AREA)

TN2014000532A 2012-06-26 2014-12-25 N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products TN2014000532A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP12004764		2012-06-26
PCT/EP2013/063118 WO2014001247A1 (fr)	2012-06-26	2013-06-24	N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments

Publications (1)

Publication Number	Publication Date
TN2014000532A1 true TN2014000532A1 (en)	2016-03-30

Family

ID=48699019

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2014000532A TN2014000532A1 (en)	2012-06-26	2014-12-25	N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products

Country Status (40)

Country	Link
US (1)	US9428460B2 (fr)
EP (1)	EP2864291B1 (fr)
JP (1)	JP6181172B2 (fr)
KR (1)	KR20150023880A (fr)
AP (1)	AP3919A (fr)
AR (1)	AR091565A1 (fr)
AU (1)	AU2013283543B2 (fr)
BR (1)	BR112014032538A2 (fr)
CA (1)	CA2877786C (fr)
CL (1)	CL2014003443A1 (fr)
CO (1)	CO7170167A2 (fr)
CR (1)	CR20140593A (fr)
CU (1)	CU20140144A7 (fr)
CY (1)	CY1118412T1 (fr)
DK (1)	DK2864291T3 (fr)
DO (1)	DOP2014000295A (fr)
EA (1)	EA028063B1 (fr)
EC (1)	ECSP14032516A (fr)
ES (1)	ES2609455T3 (fr)
HR (1)	HRP20161745T1 (fr)
HU (1)	HUE032306T2 (fr)
IL (1)	IL236146B (fr)
JO (1)	JO3342B1 (fr)
LT (1)	LT2864291T (fr)
MA (1)	MA37700B1 (fr)
ME (1)	ME02590B (fr)
MX (1)	MX2014016054A (fr)
NZ (1)	NZ703100A (fr)
PE (1)	PE20150154A1 (fr)
PH (1)	PH12014502869B1 (fr)
PL (1)	PL2864291T3 (fr)
PT (1)	PT2864291T (fr)
RS (1)	RS55500B1 (fr)
SG (1)	SG11201408254UA (fr)
SI (1)	SI2864291T1 (fr)
TN (1)	TN2014000532A1 (fr)
TW (1)	TWI600646B (fr)
UA (1)	UA115447C2 (fr)
UY (1)	UY34881A (fr)
WO (1)	WO2014001247A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015164374A1 (fr) *	2014-04-22	2015-10-29	Nimbus Iris, Inc.	Inhibiteurs d'irak et leurs utilisation
UY36391A (es) *	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
TWI726969B (zh)	2016-01-11	2021-05-11	比利時商健生藥品公司	用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
JP2019519485A (ja)	2016-05-04	2019-07-11	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
CN109311816A (zh) *	2016-05-04	2019-02-05	百时美施贵宝公司	吲哚胺2,3-双加氧酶的抑制剂及其使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5328821A (en)	1991-12-12	1994-07-12	Robyn Fisher	Cold and cryo-preservation methods for human tissue slices
US6566372B1 (en) *	1999-08-27	2003-05-20	Ligand Pharmaceuticals Incorporated	Bicyclic androgen and progesterone receptor modulator compounds and methods
AU2001268040A1 (en)	2000-06-23	2002-01-08	Eli Lilly And Company	Methods and compounds for inhibiting mrp1
JP4342935B2 (ja)	2001-06-22	2009-10-14	協和発酵キリン株式会社	肝細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
AU2003261974A1 (en)	2002-09-11	2004-04-30	Kureha Chemical Industry Company, Limited	Amine compounds and use thereof
US20050227932A1 (en)	2002-11-13	2005-10-13	Tianbao Lu	Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
ATE440087T1 (de)	2003-01-30	2009-09-15	Boehringer Ingelheim Pharma	2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
SE0302573D0 (sv)	2003-09-26	2003-09-26	Astrazeneca Ab	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US20070185148A1 (en)	2004-03-17	2007-08-09	Glaxo Group Limited	M3 muscarinic acetylchoine receptor antagonists
SE0401342D0 (sv)	2004-05-25	2004-05-25	Astrazeneca Ab	Therapeutic compounds
WO2005117570A1 (fr)	2004-05-27	2005-12-15	Jack Saffron	Coupelle pour aliments empechant l'infestation par des parasites
SG155229A1 (en)	2004-11-09	2009-09-30	Smithkline Beecham Corp	Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
JO2787B1 (en) *	2005-04-27	2014-03-15	امجين إنك,	Alternative amide derivatives and methods of use
GB0509227D0 (en)	2005-05-05	2005-06-15	Chroma Therapeutics Ltd	Intracellular enzyme inhibitors
GB0509224D0 (en)	2005-05-05	2005-06-15	Chroma Therapeutics Ltd	Inhibitors of intracellular enzymatic activity
US20060293341A1 (en)	2005-06-23	2006-12-28	Vrej Jubian	Alkyl sulfonamide derivatives
US20090240070A1 (en)	2006-02-06	2009-09-24	Showa Denko K.K.	Whitening dermatological preparations
WO2007146824A2 (fr)	2006-06-08	2007-12-21	Array Biopharma Inc.	Quinolines et méthodes d'utilisation
GB0619753D0 (en)	2006-10-06	2006-11-15	Chroma Therapeutics Ltd	Enzyme inhibitors
WO2008064432A1 (fr)	2006-12-01	2008-06-05	The University Of Sydney	Composés moléculaires polycycliques
JP5634263B2 (ja)	2007-08-16	2014-12-03	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	キナゾリンジオンキマーゼ阻害剤
JP5535925B2 (ja) *	2007-10-26	2014-07-02	ザリージェンツオブザユニバーシティオブカリフォルニア	アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
JP5699075B2 (ja)	2008-05-14	2015-04-08	アムジエン・インコーポレーテツド	癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ
MX2011003363A (es)	2008-10-01	2011-04-27	Ludwig Inst Cancer Res	Metodos para el tratamiento de cancer.
WO2011011303A1 (fr)	2009-07-21	2011-01-27	Gilead Sciences, Inc.	Inhibiteurs de virus flaviviridae
CN102481294A (zh)	2009-09-11	2012-05-30	拜耳医药股份有限公司	作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲
US9050334B2 (en)	2010-07-16	2015-06-09	Innov88 Llc	MIF inhibitors and their uses

2013
- 2013-06-24 SG SG11201408254UA patent/SG11201408254UA/en unknown
- 2013-06-24 JP JP2015519023A patent/JP6181172B2/ja not_active Expired - Fee Related
- 2013-06-24 PT PT137313250T patent/PT2864291T/pt unknown
- 2013-06-24 ES ES13731325.0T patent/ES2609455T3/es active Active
- 2013-06-24 DK DK13731325.0T patent/DK2864291T3/en active
- 2013-06-24 PL PL13731325T patent/PL2864291T3/pl unknown
- 2013-06-24 ME MEP-2016-292A patent/ME02590B/fr unknown
- 2013-06-24 EA EA201500039A patent/EA028063B1/ru not_active IP Right Cessation
- 2013-06-24 AU AU2013283543A patent/AU2013283543B2/en not_active Ceased
- 2013-06-24 HR HRP20161745TT patent/HRP20161745T1/hr unknown
- 2013-06-24 SI SI201330440A patent/SI2864291T1/sl unknown
- 2013-06-24 MX MX2014016054A patent/MX2014016054A/es unknown
- 2013-06-24 NZ NZ703100A patent/NZ703100A/en not_active IP Right Cessation
- 2013-06-24 UA UAA201500561A patent/UA115447C2/uk unknown
- 2013-06-24 BR BR112014032538A patent/BR112014032538A2/pt not_active Application Discontinuation
- 2013-06-24 US US14/408,876 patent/US9428460B2/en not_active Expired - Fee Related
- 2013-06-24 LT LTEP13731325.0T patent/LT2864291T/lt unknown
- 2013-06-24 WO PCT/EP2013/063118 patent/WO2014001247A1/fr not_active Ceased
- 2013-06-24 EP EP13731325.0A patent/EP2864291B1/fr active Active
- 2013-06-24 AP AP2014008141A patent/AP3919A/en active
- 2013-06-24 JO JOP/2013/0192A patent/JO3342B1/ar active
- 2013-06-24 CA CA2877786A patent/CA2877786C/fr not_active Expired - Fee Related
- 2013-06-24 PE PE2014002495A patent/PE20150154A1/es active IP Right Grant
- 2013-06-24 KR KR20157001996A patent/KR20150023880A/ko not_active Ceased
- 2013-06-24 RS RS20161149A patent/RS55500B1/sr unknown
- 2013-06-24 HU HUE13731325A patent/HUE032306T2/en unknown
- 2013-06-24 MA MA37700A patent/MA37700B1/fr unknown
- 2013-06-26 TW TW102122775A patent/TWI600646B/zh not_active IP Right Cessation
- 2013-06-26 AR ARP130102253 patent/AR091565A1/es unknown
- 2013-06-26 UY UY0001034881A patent/UY34881A/es not_active Application Discontinuation
2014
- 2014-12-09 IL IL236146A patent/IL236146B/en active IP Right Grant
- 2014-12-18 CR CR20140593A patent/CR20140593A/es unknown
- 2014-12-18 CL CL2014003443A patent/CL2014003443A1/es unknown
- 2014-12-18 CU CUP2014000144A patent/CU20140144A7/es unknown
- 2014-12-19 CO CO14279115A patent/CO7170167A2/es unknown
- 2014-12-19 EC ECIEPI201432516A patent/ECSP14032516A/es unknown
- 2014-12-19 DO DO2014000295A patent/DOP2014000295A/es unknown
- 2014-12-22 PH PH12014502869A patent/PH12014502869B1/en unknown
- 2014-12-25 TN TN2014000532A patent/TN2014000532A1/fr unknown
2016
- 2016-12-23 CY CY20161101343T patent/CY1118412T1/el unknown

Also Published As

Publication number	Publication date
JO3342B1 (ar)	2019-03-13
MA37700B1 (fr)	2018-03-30
UA115447C2 (uk)	2017-11-10
AU2013283543A1 (en)	2015-01-29
MX2014016054A (es)	2015-04-10
HRP20161745T1 (hr)	2017-02-24
DOP2014000295A (es)	2015-01-31
AP3919A (en)	2016-11-30
ECSP14032516A (es)	2015-12-31
DK2864291T3 (en)	2017-01-16
BR112014032538A2 (pt)	2017-06-27
CU20140144A7 (es)	2015-08-27
PL2864291T3 (pl)	2017-07-31
AR091565A1 (es)	2015-02-11
EA201500039A1 (ru)	2015-06-30
AU2013283543B2 (en)	2017-11-02
EP2864291B1 (fr)	2016-10-05
IL236146A0 (en)	2015-02-01
ES2609455T3 (es)	2017-04-20
CR20140593A (es)	2015-02-16
JP6181172B2 (ja)	2017-08-16
CN104684896A (zh)	2015-06-03
CA2877786C (fr)	2020-08-25
PT2864291T (pt)	2017-01-06
TWI600646B (zh)	2017-10-01
TW201400460A (zh)	2014-01-01
RS55500B1 (sr)	2017-05-31
HUE032306T2 (en)	2017-09-28
KR20150023880A (ko)	2015-03-05
WO2014001247A1 (fr)	2014-01-03
SI2864291T1 (sl)	2017-01-31
AP2014008141A0 (en)	2014-12-31
CO7170167A2 (es)	2015-01-28
US9428460B2 (en)	2016-08-30
IL236146B (en)	2018-05-31
CA2877786A1 (fr)	2014-01-03
CY1118412T1 (el)	2017-06-28
SG11201408254UA (en)	2015-01-29
ME02590B (fr)	2017-06-20
EA028063B1 (ru)	2017-10-31
EP2864291A1 (fr)	2015-04-29
JP2015521641A (ja)	2015-07-30
US20150191431A1 (en)	2015-07-09
PE20150154A1 (es)	2015-02-19
MA20150269A1 (fr)	2015-08-31
CL2014003443A1 (es)	2015-06-26
PH12014502869A1 (en)	2015-02-23
UY34881A (es)	2014-01-31
NZ703100A (en)	2016-10-28
LT2864291T (lt)	2017-01-10
PH12014502869B1 (en)	2015-02-23
HK1206346A1 (en)	2016-01-08

Publication	Publication Date	Title
IN2014DN08867A (fr)	2015-05-22
PH12015501289A1 (en)	2015-08-24	Novel benzimidazole derivatives as ep4 antagonists
ZA201501372B (en)	2016-01-27	Production of soluble protein products from hemp ("h701")
PH12014501195A1 (en)	2014-09-01	Novel 2h-indazoles as ep2, receptor antagonists
TN2014000532A1 (en)	2016-03-30	N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products
MX2015003034A (es)	2015-09-29	Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
MX353062B (es)	2017-12-19	Nuevas carboxamidas heterociclicas como moduladores de la activadad de cinasas.
PH12015500322A1 (en)	2015-03-30	Tris(hetero)arylpyrazoles and use thereof
IL229604A0 (en)	2014-01-30	A new process for the synthesis of 7-chloro-4-(piperazine-1-yl)-quinoline
IN2014DN07191A (fr)	2015-04-24
MX2015005312A (es)	2015-11-16	Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
TH1401007761A (th)	2016-06-17	N-[4-(ควิโนลิน-4-อิลอกซี)ไซโคลเฮกซิล(เมธิล)](เฮเทอโร)อะริลคาร์บอกซาไมด์ ในฐานะเป็นแอนโดรเจน รีเซฟเตอร์ แอนตาโกนิสท์, การผลิต และ การใช้ของสิ่งเหล่านั้นในฐานะเป็นผลิตภัณฑ์ซึ่งมีคุณสมบัติเป็นยา
MX2016010549A (es)	2016-11-16	Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas.